Ferrara N. Vascular endothelial growth factor: molecular and biological aspects [J]. Curr Top Microbiol Immunol. 1999;237:1–30. https://doi.org/10.1007/978-3-642-59953-8_1.

Article  CAS  PubMed  Google Scholar 

Huang M, Huang B, Li G, Zeng S. Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cells. BMC Gastroenterol. 2018;18(1):169. https://doi.org/10.1186/s12876-018-0870-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu YP, Wu JJ, Tian SM, Jin T, Li C, Xie K. Apatinib with EGFR-TKIs in advanced wild gene-type NSCLC: A case report. Med (Baltim). 2019;98(1):e13924. https://doi.org/10.1097/MD.0000000000013924.

Article  CAS  Google Scholar 

Jin J, Du J, Wu Y. Apatinib monotherapy for advanced VEGFR-2-negative nasopharyngeal carcinoma: A case report. Med (Baltim). 2019;98(1):e13491. https://doi.org/10.1097/MD.0000000000013491.

Article  Google Scholar 

Liu Z, Wang C, Wu G, Cheng J. MRI analysis of hydrogel-loaded apatinib for local therapy of hepatocellular carcinoma model in nude mice. Biochem Biophys Res Commun. 2019;509(2):529–34. https://doi.org/10.1016/j.bbrc.2018.12.120.

Article  CAS  PubMed  Google Scholar 

Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8(6):467–77. https://doi.org/10.1038/nri2326.

Liu B, Song Y, Liu D. Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy. J Hematol Oncol. 2017;10(1):174. https://doi.org/10.1186/s13045-017-0541-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dedecker H, Teuwen LA, Vandamme T, Domen A, Prenen H. The role of immunotherapy in esophageal and gastric cancer. Clin Colorectal Cancer. 2023;22(2):175–82. https://doi.org/10.1016/j.clcc.2023.03.001.

Article  PubMed  Google Scholar 

Diggs LP, Hsueh EC. Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. Biomark Res. 2017. https://doi.org/10.1186/s40364-017-0093-8. 5,12.

Article  PubMed  PubMed Central  Google Scholar 

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, Mcdermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, Mcmiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, Mcdonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54. https://doi.org/10.1056/NEJMoa1200690.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134–44. https://doi.org/10.1056/NEJMoa1305133.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hodi FS, O’day SJ, Mcdermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, Van Den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. https://doi.org/10.1056/NEJMoa1003466.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schoenherr C, Pietzsch S, Barca C, Müller FE, Bahr FS, Kasten M, Zeug A, Erschow S, Falk CS, Ponimaskin E, Thackeray JT, Hilfiker-Kleiner D, Ricke-Hoch M. Immune-checkpoint-inhibitor therapy directed against PD-L1 is tolerated in the heart without manifestation of cardiac inflammation in a preclinical reversible melanoma mouse model. Front Mol Med. 2025;4:1487526. https://doi.org/10.3389/fmmed.2024.1487526.

Article  PubMed  PubMed Central  Google Scholar 

Bonotto M, Gerratana L, Poletto E, Driol P, Giangreco M, Russo S, Minisini AM, Andreetta C, Mansutti M, Pisa FE, Fasola G, Puglisi F. Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist. 2014;19(6):608–15. https://doi.org/10.1634/theoncologist.2014-0002.

Article  PubMed  PubMed Central  Google Scholar 

Liu K, Ren T, Huang Y, Sun K, Bao X, Wang S, Zheng B, Guo W. Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma. Cell Death Dis. 2017;8(8):e3015. https://doi.org/10.1038/cddis.2017.422.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Emens LA. Breast cancer immunotherapy: facts and hopes. Clin Cancer Res. 2018;24(3):511–20. https://doi.org/10.1158/1078-0432.CCR-16-3001.

Article  CAS  PubMed  Google Scholar 

Yu X, Fan H, Jiang X, Zheng W, Yang Y, Jin M, Ma X, Jiang W. Apatinib induces apoptosis and autophagy via the PI3K/AKT/mTOR and MAPK/ERK signaling pathways in neuroblastoma. Oncol Lett. 2020;20(4):52. https://doi.org/10.3892/ol.2020.11913.

Qiu XY, Hu DX, Chen WQ, Chen RQ, Qian SR, Li CY, Li YJ, Xiong XX, Liu D, Pan F, Yu SB, Chen XQ. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation. Biochim Biophys Acta Mol Basis Dis. 2018;1864(5 Pt A):1754–69. https://doi.org/10.1016/j.bbadis.2018.03.002.

Article  CAS  PubMed  Google Scholar 

Zhao W, Ma N, Wang S, Mo Y, Zhang Z, Huang G, Midorikawa K, Hiraku Y, Oikawa S, Murata M, Takeuchi K. RERG suppresses cell proliferation, migration and angiogenesis through ERK/NF-κB signaling pathway in nasopharyngeal carcinoma. J Exp Clin Cancer Res. 2017;36(1):88. https://doi.org/10.1186/s13046-017-0554-9.

Pires BR, Mencalha AL, Ferreira GM, De Souza WF, Morgado-Díaz JA, Maia AM, Corrêa S, Abdelhay ES. NF-kappaB is involved in the regulation of EMT genes in breast cancer cells. PLoS ONE. 2017;12(1):e0169622. https://doi.org/10.1371/journal.pone.0169622.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao S, Ren S, Jiang T, Zhu B, Li X, Zhao C, Jia Y, Shi J, Zhang L, Liu X, Qiao M, Chen X, Su C, Yu H, Zhou C, Zhang J, Camidge DR, Hirsch FR. Low-Dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 Blockade in lung cancer. Cancer Immunol Res. 2019;7(4):630–43. https://doi.org/10.1158/2326-6066.CIR-17-0640.

Article  CAS  PubMed  Google Scholar 

Zhang Y, Wang F, Sun HR, Huang YK, Gao JP, Huang H. Apatinib combined with PD-L1 Blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer. J Cancer Res Clin Oncol. 2021;147(8):2209–22. https://doi.org/10.1007/s00432-021-03633-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou C, Wang Y, Zhao J, Chen G, Liu Z, Gu K, Huang M, He J, Chen J, Ma Z, Feng J, Shi J, Yu X, Cheng Y, Yao Y, Chen Y, Guo R, Lin X, Wang Z, Gao G, Wang Q, Li W, Yang X, Wu L, Zhang J, Ren S. Efficacy and biomarker analysis of camrelizumab in combination with apatinib in patients with advanced nonsquamous NSCLC previously treated with chemotherapy. Clin Cancer Res. 2021;27(5):1296–304. https://doi.org/10.1158/1078-0432.CCR-20-3136.

Article  CAS  PubMed  Google Scholar 

Schmittnaegel M, Rigamonti N, Kadioglu E, Cassará A, Wyser Rmili C, Kiialainen A, Kienast Y, Mueller HJ, Ooi CH, Laoui D, De Palma M. Dual angiopoietin-2 and VEGFA Inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint Blockade. Sci Transl Med. 2017;9(385):eaak9670. https://doi.org/10.1126/scitranslmed.aak9670.

Article  CAS  PubMed  Google Scholar 

Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, Feyen K, Tawney J, Hanahan D, Michael IP, Bergers G. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017;9(385):eaak9679. https://doi.org/10.1126/scitranslmed.aak9679.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Q, Gao J, Di W, Wu X. Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 Blockade in VEGFA-overexpressed mouse tumor models. Cancer Immunol Immunother. 2020;69(9):1781–99. https://doi.org/10.1007/s00262-020-02576-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hamzah J, Jugold M, Kiessling F, Rigby P, Manzur M, Marti HH, Rabie T, Kaden S, Gröne HJ, Hämmerling GJ, Arnold B, Ganss R. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature. 2008;453(7193):410–4. https://doi.org/10.1038/nature06868.

Article  CAS  PubMed